Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …
China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …
Alvotech, the biosim specialist locked in a legal battle over AbbVie’s sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic …
Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …
It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …
Sandoz’s biosimilar of Neulasta, or pegfilgrastim, matched the reference product in a clinical trial, according to the company. Researchers found equivalence in pharmacokinetics, pharmacodynamics, immunogenicity …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
